Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies

European Journal of Nuclear Medicine

Volumn 29, Issue 11, 2002, Pages 1470-1477

  Bartlett, Marissa L ^a   Webb, Myles ^a   Durrant, Simon ^a   Morton, James A ^a   Allison, Roger ^a   Macfarlane, David J ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Bone marrow transplantation; Dosimetry; Nuclear medicine; Radionuclide therapy

Indexed keywords

CYCLOPHOSPHAMIDE; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ADULT; AGED; ARTICLE; BLADDER; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; CASE REPORT; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG HALF LIFE; FEMALE; HUMAN; LIVER; MALE; MULTIPLE MYELOMA; MYELOFIBROSIS; RADIATION DOSE; SIDE EFFECT; STEM CELL; ANTIBODY SPECIFICITY; BLOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOMETRY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WHOLE BODY COUNTING;

BONE MARROW; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; MULTIPLE MYELOMA; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 0036034968     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0934-y     Document Type: Article

References (16)

1. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-1123.
2. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: An experimental model in the rat. Nucl Med Commun 1992; 13:321-329.
3. 52Fe before bone marrow transplantation. Bone Marrow Transpl 1997; 19:191-196.
4. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158-3162.
5. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys 2000; 78:199-214.
6. 153Sm]EDTMP: A potential therapy for bone cancer pain. Semin Nucl Med 1992; 22:41-45.
7. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34:1031-1036.
8. Bayouth JE, Macey DJ, Boyer AL, Champlin RE. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Med Phys 1995; 22:743-753.
9. Bartlett ML, Macfarlane DJ. Estimating uptake in liver and abdominal tumours for radionuclide therapy dosimetry. Nucl Med Commun 2002; 23:743-748.
10. Plaizier MA, Roos JC, Teule GJ, van Dieren EB, den Hollander W, Haisma HJ, DeJager RL, van Lingen A. Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies. Eur J Nucl Med 1994; 21:216-222.
11. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
12. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35:63-69.
13. Bayouth JE, Macey DJ. Dosimetry considerations of bone-seeking radionuclides for marrow ablation. Med Phys 1993; 20:1089-1096.
14. Bayouth JE, Macey DJ. Quantitative imaging of holmium-166 with an Anger camera. Phys Med Biol 1994; 39:265-279.
15. Bayouth JE, Macey DJ, Kasi LP, Garlich JR, McMillan K, Dimopoulos MA, Champlin RE. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995; 36:730-737.
16. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31:1257-1280.